SOURCE: The Bedford Report

The Bedford Report

April 13, 2011 08:16 ET

Volatility Persists for Xoma and Aastrom Biosciences

The Bedford Report Provides Analyst Research on Xoma & Aastrom Biosciences

NEW YORK, NY--(Marketwire - Apr 13, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Xoma Limited (NASDAQ: XOMA) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Access to the full company reports can be found at:

www.bedfordreport.com/2011-04-XOMA

www.bedfordreport.com/2011-04-ASTM

Last month, shares of Xoma took a significant hit after the company announced that its potential diabetes drug failed to lower blood sugar of patients more than a placebo in a clinical trial. On the upside, the company said patients receiving the drug candidate did show significant declines in C-reactive protein, a tell-tale sign for risk of heart attack, stroke and other cardiovascular diseases. The company plans to further develop the drug as a treatment for Behcet's uveitis.

Stem cell research firm, Aastrom Biosciences is attempting to develop the first treatment for critical limb ischemia (CLI). This is a potential $2 billion a year market as there are currently no drugs approved by the Food and Drug Administration for CLI.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information